Galderma stock: Sales outlook raised after strong nine-month growth

Published on 10/31/2026 at 10:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galderma stock enters the weekend after stronger nine-month sales prompted a higher 2026 growth outlook. China also approved Relfydess.

Key developments for Galderma

Galderma lifted its 2026 constant-currency sales-growth outlook to 22.5% to 23.5% after strong nine-month performance.
Relfydess received Chinese approval for the temporary improvement of moderate-to-severe frown lines in adults.
Therapeutic Dermatology, Dermatological Skincare and Neuromodulators supported the stronger sales trajectory.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma reported strong nine-month performance on Thursday, October 22, and raised its full-year sales outlook. The dermatology group said net sales reached USD 4.765 billion in the first nine months of 2026, up 25.1% year on year at constant currency, according to its company release.

Galderma raised its 2026 constant-currency net-sales growth guidance to 22.5% to 23.5%, from 19% to 21% previously. It maintained its expectation for a Core EBITDA margin of approximately 26% at constant currency. The outlook excludes the potential contribution from the planned ZO Skin Health acquisition, which the company expects to close in the fourth quarter of 2026 or early 2027.

Portfolio expansion adds another catalyst

The company said third-quarter sales grew 26.0% year on year at constant currency. Therapeutic Dermatology was a major contributor, with Nemluvio and the mature portfolio supporting momentum alongside Dermatological Skincare and Neuromodulators.

On Friday, October 23, China's National Medical Products Administration approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults. Galderma said the ready-to-use liquid neuromodulator was already authorized in more than 35 markets. The approval broadens the addressable market for the Injectable Aesthetics portfolio in China, as reported in the investor release.

Galderma stock traded at 209.50 euros on Lang & Schwarz at 10:27 CET on Saturday, October 31. The next focus for investors is execution against the upgraded sales trajectory, continued rollout of newer dermatology products and progress toward the ZO Skin Health transaction.